This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Cabergoline on Weight and Glucose Tolerance

This study has been completed.
Information provided by (Responsible Party):
Judith Korner, Columbia University Identifier:
First received: July 14, 2011
Last updated: October 13, 2015
Last verified: October 2015

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Condition Intervention Phase
Body Weight Impaired Glucose Tolerance in Obese Drug: Cabergoline Other: placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

Resource links provided by NLM:

Further study details as provided by Judith Korner, Columbia University:

Primary Outcome Measures:
  • body weight [ Time Frame: 16 weeks ]

Secondary Outcome Measures:
  • glucose [ Time Frame: 16 weeks ]

Enrollment: 40
Study Start Date: April 2002
Study Completion Date: July 2011
Primary Completion Date: September 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo
placebo pill
Other: placebo
1 pill twice weekly
Active Comparator: cabergoline
cabergoline pill
Drug: Cabergoline
cabergoline 0.5 mg twice weekly


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 18 - 55 years
  • BMI 30 -40

Exclusion Criteria:

  • diabetes,
  • clinically significant medical condition,
  • use of medications that effect blood glucose or body weight
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01395602

United States, New York
Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Principal Investigator: Judith Korner, MD, PHD Columbia University
  More Information

Responsible Party: Judith Korner, Associate Professor of Medicine, Columbia University Identifier: NCT01395602     History of Changes
Other Study ID Numbers: IRB #13952
Study First Received: July 14, 2011
Last Updated: October 13, 2015

Additional relevant MeSH terms:
Body Weight
Glucose Intolerance
Signs and Symptoms
Glucose Metabolism Disorders
Metabolic Diseases
Antineoplastic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on August 22, 2017